The Motley Fool on MSN13d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
Yahoo25d
“We’ve never been limited to traditional categories” – Arc'teryx goes all in on technical mountain running shoes for 2025
The first Vertex shoe was released six years ago and the brand went back to the drawing board to redesign the original. Over hundreds of test models and thousands of miles put in by Arc'teryx ...
BioPharma Dive18d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex price target raised to $60 from $57 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...